|
2025 Journal Article A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infectionThomson, Rachel M., Burke, Andrew J., Morgan, Lucy C. and Colin, Andrew A. (2025). A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infection. Annals of the American Thoracic Society. doi: 10.1513/annalsats.202407-745rl |
|
2025 Journal Article Infection by clonally related Mycobacterium abscessus isolates: the role of drinking waterThomson, Rachel M., Wheeler, Nicole, Stockwell, Rebecca E., Bryant, Josephine, Taylor, Steven L, Leong, Lex E. X., Le, Trieu, Rogers, Geraint B, Carter, Robyn, Sherrard, Laura J, Powell, Harry, Simpson, Graham, Patterson-Fahy, Kirby, Wainwright, Claire E., Floto, R. Andres, Parkhill, Julian and Bell, Scott C. (2025). Infection by clonally related Mycobacterium abscessus isolates: the role of drinking water. American Journal of Respiratory and Critical Care Medicine, 211 (5), 842-853. doi: 10.1164/rccm.202409-1824oc |
|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trialHicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2025 Conference Publication The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CFDuplancic, C., Alene, K., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A. and Bell, S. (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Journal Article Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis RegistryWebb, Elizabeth M., Holland, Anne E., Chang, Anne B., Middleton, Peter G., Thomson, Rachel, Wong, Conroy, Jayaram, Lata, Holmes‐Liew, Chien‐Li, Morgan, Lucy and Lee, Annemarie L. (2024). Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry. Pediatric Pulmonology, 60 (1) e27370, e27370. doi: 10.1002/ppul.27370 |
|
2024 Journal Article Current physiotherapy practice for adults with bronchiectasis: data from the Australian Bronchiectasis RegistryWebb, Elizabeth M., Holland, Anne E., Chang, Anne B., Burr, Lucy, Holmes-Liew, Chien-Li, King, Paul T., Middleton, Peter G., Morgan, Lucy, Thomson, Rachel M., Wong, Conroy and Lee, Annemarie L. (2024). Current physiotherapy practice for adults with bronchiectasis: data from the Australian Bronchiectasis Registry. Respiratory Medicine, 233 107777, 1-8. doi: 10.1016/j.rmed.2024.107777 |
|
2024 Journal Article Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles S., Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy C., O'Donnell, Anne E., Ringshausen, Felix C., Sibila, Oriol, Thomson, Rachel M., Carroll, Kevin J., Pontenani, Federica, Castellani, Paola, Chalmers, James and PROMIS Trial Investigators, (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. Lancet Respiratory Medicine, 12 (10), 787-798. doi: 10.1016/-2600(24)00225-X |
|
2024 Conference Publication RCT Abstract - Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy, O'Donnell, Anne, Ringhausen, Felix, Sibila, Oriol, Thomson, Rachel, Carroll, Kevin, Pontenani, Federica, Castellani, Paola and Chalmers, James (2024). RCT Abstract - Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. European Respiratory Society. doi: 10.1183/13993003.congress-2024.rct5390 |
|
2024 Journal Article Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles S, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy C, O'Donnell, Anne E, Ringshausen, Felix C, Sibila, Oriol, Thomson, Rachel M, Carroll, Kevin J, Pontenani, Federica, Castellani, Paola and Chalmers, James D (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. The Lancet Respiratory Medicine, 12 (10), 787-798. doi: 10.1016/s2213-2600(24)00225-x |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trialRice, Megan, Hicks, Daniel, Jong, Tiffany, Gailer, Nicolas, Joshi, Sri, Stevens, Luke, Lee, Kate, Thomson, Rachel, Burke, Andrew, Grimwood, Keith, Bell, Scott, Clark, Julia and Wainwright, Claire E. (2024). Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national studyDuplancic, Christine, Wainwright, Claire, Thomson, Rachel, Rogers, Geraint, Clements, Archie, Floto, Andre and Bell, Scott (2024). Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT)Hicks, D., Jong, T., Rice, M., Gailer, N., Joshi, S., Stevens, L., Lee, K., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2024). Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT). 47th European Cystic Fibrosis Conference, Glasgow, United Kingdom, 5-8 June 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(24)00244-3 |
|
2024 Conference Publication Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients Mishiro, K., Ballard, E., Goh, F. and Thomson, R. (2024). Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients . American Thoracic Society International Conference 2024, San Diego, CA United States, 17-22 May 2024. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3158 |
|
2024 Journal Article OPTIMA: an open-label, non-comparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infectionThomson, Rachel M., Loebinger, Michael R., Burke, Andrew J., Morgan, Lucy C., Waterer, Grant W. and Ganslandt, Cecilia (2024). OPTIMA: an open-label, non-comparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infection. Annals of the American Thoracic Society, 21 (4), 568-576. doi: 10.1513/annalsats.202306-532oc |
|
2024 Conference Publication Identification of Staphylococcus aureus hypermutator strain through metagenomic sputum analysisTaylor, S., Bryant, J., Kyany'a, C., Duplancic, C., Sims, S., Elms, L., Thomson, R., Rogers, G., Bell, S. and Investigators, A. (2024). Identification of Staphylococcus aureus hypermutator strain through metagenomic sputum analysis. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, Adelaide, SA, Australia, 22–26 March 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Mycobacteria acquisition from potable waterRamsay, K., Smith, K., Carter, R., Clayton, M., Thomson, R. and Bell, S. (2024). Mycobacteria acquisition from potable water. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science,, Gold Coast, QLD, Australia, 22-26 March 2024. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/resp.14673 |
|
2024 Conference Publication Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national studyDuplancic, C., Wainwright, C., Thomson, R., Rogers, G., Clements, A., Floto, R. and Bell, S. (2024). Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study. TSANZSRS 2024 The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science, Adelaide, SA, Australia, 22–26 March 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2023 Journal Article Things They Are a Changing in the Field of Nontuberculous MycobacteriaKasperbauer, Shannon and Thomson, Rachel (2023). Things They Are a Changing in the Field of Nontuberculous Mycobacteria. Clinics in Chest Medicine, 44 (4), xiii-xiv. doi: 10.1016/j.ccm.2023.09.001 |
|
2023 Journal Article Extended water stagnation in buildings during the COVID-19 pandemic increases the risks posed by opportunistic pathogensHuang, Casey K., Weerasekara, Anjani, Lu, Ji, Carter, Robyn, Weynberg, Karen D., Thomson, Rachel, Bell, Scott and Guo, Jianhua (2023). Extended water stagnation in buildings during the COVID-19 pandemic increases the risks posed by opportunistic pathogens. Water Research: X, 21 100201, 100201. doi: 10.1016/j.wroa.2023.100201 |
|
2023 Journal Article In vitro susceptibility testing of imipenem- relebactam and tedizolid against 102 Mycobacterium abscessus isolatesBurke, Andrew, Carter, Robyn, Tolson, Carla, Congdon, Jacob, Duplancic, Christine, Bursle, Evan, Bell, Scott C., Roberts, Jason A. and Thomson, Rachel (2023). In vitro susceptibility testing of imipenem- relebactam and tedizolid against 102 Mycobacterium abscessus isolates. International Journal of Antimicrobial Agents, 62 (4) 106938, 1-6. doi: 10.1016/j.ijantimicag.2023.106938 |
